Allergan (AGN) Beats On Q1 Earnings & Sales, Raises '19 View
Zacks Investment Research | May 06, 2019 09:27PM ET
Allergan plc’s (NYSE:AGN) first-quarter adjusted earnings came in at $3.79 per share, which beat the Zacks Consensus Estimate of $3.55 and came ahead of the guidance of $3.40 and $3.60. Earnings rose 1.3% year over year.
Revenues came in at $3.60 billion, which exceeded the Zacks Consensus Estimate of $3.53 billion as well as the guidance of $3.4 billion to $3.55 billion. Revenues fell 2% from the year-ago period primarily due to loss of exclusivity on some brands and divestitures of some others in 2018.
Moreover, sales of Allergan’s blockbuster eye drug, Restasis also declined in the quarter ahead of anticipated generic competition. Also, declines in textured breast implants in certain international markets hurt sales. However, key products like Botox (cosmetic and therapeutics), Juvéderm collection of fillers, Vraylar, and Lo Loestrin pulled up the top line in the quarter.
Allergan said that its core business (Medical Aesthetics, CNS, Eye Care and GI), comprising more than 80% of total revenues, grew 4.4% year on year in the quarter.
Segment Discussion
Allergan reports revenues under three segments – U.S. General Medicine, U.S. Specialized Therapeutics and International.
U.S. Specialized net revenues declined 2.3% to $1.54 billion. Strong sales growth of its facial aesthetics products, Botox and Juvéderm and Botox Therapeutic was offset by decline in sales of Restasis and divestiture of Medical Dermatology business in September 2018.
In Facial Aesthetics, Botox (cosmetic) raked in sales of $229.5 million, up 16.7% year over year. Juvéderm collection of fillers rose 5.6% to $129.7 million
Alloderm sales, however, fell 4.5% to $95.0 million while CoolSculpting sales of $62.9 million declined 27.8% year over year.
In Eye Care, while Ozurdex sales rose 18.8% to $30.3 million, Restasis sales fell 9.4% to $231.7 million. Restasis sales decreased due to lower selling price.
Botox Therapeutic revenues were $397.6 million, up 5.8% year over year.
There have been concerns regarding possible new competitors to Botox. The entry of CGRP antibodies may have a negative impact on sales of Botox Therapeutics, mainly for the chronic migraine indication. Amgen (NASDAQ:AMGN) , Eli Lilly (NYSE:LLY) and Teva Pharma’s (NYSE:TEVA) CGRP migraine treatments, Aimovig, Emgality and Ajovy, respectively were all launched in 2018.
Meanwhile, in February, Evolus’ Jeuveau injection indicated to improve the appearance of glabellar or frown lines was approved by the FDA, which can pose competition to Botox. Revance Therapeutics is developing RT002, a rival treatment to Botox for the frown lines indication, which has demonstrated longer duration of efficacy compared to Botox in late-stage studies.
Get The News You Want
U.S. General Medicine net revenues were up 2.1% year over year to $1.25 billion in the reported quarter as strong growth of Vraylar, Linzess and Lo Loestrin was offset by lower sales of drugs like Namenda XR and Estrace due to generic competition.
Linzess sales rose 1.3% to $161.3 million. Lo Loestrin sales grew 9.8% to $125.8 million while Bystolic sales fell 3.4% to $128.3 million. Vraylar sales were $143.7 million in the first quarter, 70.3% higher than the year-ago quarter, while Viibryd sales were $85 million, up 18.5% from the year-ago quarter.
The International segment recorded net revenues of $801.5 million, up 1.3% from the year-ago period, excluding the impact of foreign exchange as growth in Facial Aesthetics and Botox (therapeutic) was partially offset by regulatory changes for textured breast implants and lower glaucoma and eye drop revenues.
Profits Decline
Adjusted operating income decreased 7.6% to $1.63 billion in the first quarter due to the impact of divestitures, loss of exclusivity of some products and a decline in Restasis.
Selling, general and administrative (SG&A) expenses increased 4.5% to $1.10 billion in the first quarter owing to higher marketing spending in Medical Aesthetics.
Research and development (R&D) expenses rose 11.8% to $397.9 million due to pipeline progress.
2019 Guidance
Allergan slightly raised its earnings and sales guidance for 2019. Allergan expects sales to be in the range of $15.13-$15.43 billion, up from the previous guidance of $15.0-$15.3 billion.
The company estimates its adjusted earnings to be more than $16.55 per share versus equal to or greater than$16.36 per share expected previously.
Adjusted tax rate is expected to be approximately 13-13.5% in 2019. Adjusted R&D expenses are expected to be approximately $1.6 - $1.7 billion and SG&A spend is expected to be approximately $4.1 - $4.3 billion. Adjusted gross margin is expected to be approximately 85%-85.5%.
For the second quarter, the company expects revenues to be in the range of $3.88 billion to $4.03 billion and earnings per share between $4.20 and $4.40.
Our Take
Allergan’s stock was down slightly in pre-market trading despite beating estimates for both earnings and sales in the first quarter and marginally boosting its guidance. So far this year, Allergan’s share price has risen 10.5% compared with the the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.